NCT00421980已完成3 期
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2002年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 84
- 试验地点
- 1
研究概览
简要总结
The primary objective of this study was to determine the long-term safety of etanercept in adults with AS who had completed study 0881A3-311-EU.
详细描述
This was an open-label, multicenter extension study that was conducted to evaluate the safety and efficacy of etanercept in the treatment of adult subjects with AS who had completed study 0881A3-311-EU. The study consisted of an open-label treatment period of up to approximately 96 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 66 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Completed the entire 12 weeks of therapy in study 0881A3-311-EU, or completed at least 8 weeks of therapy and returned for the week 12 visit in study 0881A3-311-EU.
- •Negative serum β-HCG pregnancy test at baseline (all women of childbearing potential).
- •Sexually active women of childbearing potential had to use a medically acceptable form of contraception. Medically acceptable forms of contraception included oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception. Additionally, the use of condoms was suggested as an adjunct to the methods previously addressed to protect against sexually transmitted diseases and to provide additional protection against accidental pregnancy.
- •Sexually active men had to agree to use a medically accepted form of contraception during the study.
- •Able to reconstitute and self-inject test article or have a designee who can do so.
- •Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol-specific procedures were performed.
- •Able to store injectable test article at 2°C to 8°C.
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
16.0040 Ankylosing Spondylitis StudyAnkylosing SpondylitisNCT00356356Amgen257
已完成
3 期
Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque PsoriasisPediatric Plaque PsoriasisNCT00141921Amgen182
已完成
不适用
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in SpainInflammationRheumatoid ArthritisNCT00195364Wyeth is now a wholly owned subsidiary of Pfizer93
已完成
2 期
Study of the Efficacy and Safety of Etanercept in Adults With VitiligoVitiligoNCT00134368University of Medicine and Dentistry of New Jersey40
已完成
3 期
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012Rheumatoid ArthritisNCT00356590Amgen468